Risk Of Developing Liver Cancer After HCV Treatment

Tuesday, February 14, 2017

Discovery of counterfeit hepatitis C drug is another example of why importation is bad for patients

Discovery of counterfeit hepatitis C drug is another example of why importation is bad for patients
Nicole Longo
The manufacturing and trafficking of counterfeit drugs is not just a U.S. concern but a growing threat globally. Governments around the world are working together to try to prevent these fake products from reaching and harming patients. While the U.S. market is the most secure with a closed supply chain, there remains the threat of counterfeit and adulterated drugs reaching U.S. patients. This risk increases dramatically if medicines are imported from and travel through other countries before reaching the United States because there would be no way to ensure the safety and efficacy of those products

No comments:

Post a Comment